纳米颗粒作为癌症治疗的新型药物传递系统:现状和未来展望。

IF 2.6 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Kai Bin Liew, Hiu Ching Phang, Vinie Ying Xuan Tan, Phei Er Kee, Long Chiau Ming, Palanirajan Vijayarajkumar Kumar, Siew-Keah Lee, A B M Helal Uddin, Ritu M Gilhotra, Arya Kadukkattil Ramanunny
{"title":"纳米颗粒作为癌症治疗的新型药物传递系统:现状和未来展望。","authors":"Kai Bin Liew, Hiu Ching Phang, Vinie Ying Xuan Tan, Phei Er Kee, Long Chiau Ming, Palanirajan Vijayarajkumar Kumar, Siew-Keah Lee, A B M Helal Uddin, Ritu M Gilhotra, Arya Kadukkattil Ramanunny","doi":"10.2174/0113816128368718250320060346","DOIUrl":null,"url":null,"abstract":"<p><p>Cancer continues to pose a significant global health challenge, demanding innovative therapeutic approaches to overcome the limitations of conventional treatments like chemotherapy and radiotherapy. Nanoparticles (NPs) have emerged as promising tools for cancer therapy due to their unique physicochemical properties that enable targeted drug delivery, reduced systemic toxicity, and enhanced therapeutic efficacy. This comprehensive review delves into the mechanisms of NP-based drug delivery, highlighting both passive and active targeting strategies. It categorizes and discusses diverse NP types, including polymeric, lipid-based, and metallic nanoparticles, emphasizing their applications in enhancing the bioavailability and specificity of anticancer agents. This review also explores the integration of advanced technologies, such as theranostics and artificial intelligence, to optimize NP design and functionality for personalized medicine. However, challenges remain, including issues related to toxicity, drug resistance, and manufacturing scalability. Addressing these barriers requires interdisciplinary research focused on developing stimuli-responsive NPs, improving biocompatibility, and incorporating multimodal therapeutic platforms. Although substantial progress has been made, this review is limited by the paucity of clinical trials validating NP efficacy and safety in diverse patient populations. Future endeavors should prioritize translational research to bridge the gap between preclinical innovations and clinical applications, ensuring that these transformative technologies benefit a broader spectrum of cancer patients. The review underscores the immense potential of NPs in redefining cancer treatment while advocating for sustained research to address existing limitations and unlock their full therapeutic promise.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.6000,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Nanoparticles as Novel Drug Delivery Systems for Cancer Treatment: Current Status and Future Perspectives.\",\"authors\":\"Kai Bin Liew, Hiu Ching Phang, Vinie Ying Xuan Tan, Phei Er Kee, Long Chiau Ming, Palanirajan Vijayarajkumar Kumar, Siew-Keah Lee, A B M Helal Uddin, Ritu M Gilhotra, Arya Kadukkattil Ramanunny\",\"doi\":\"10.2174/0113816128368718250320060346\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Cancer continues to pose a significant global health challenge, demanding innovative therapeutic approaches to overcome the limitations of conventional treatments like chemotherapy and radiotherapy. Nanoparticles (NPs) have emerged as promising tools for cancer therapy due to their unique physicochemical properties that enable targeted drug delivery, reduced systemic toxicity, and enhanced therapeutic efficacy. This comprehensive review delves into the mechanisms of NP-based drug delivery, highlighting both passive and active targeting strategies. It categorizes and discusses diverse NP types, including polymeric, lipid-based, and metallic nanoparticles, emphasizing their applications in enhancing the bioavailability and specificity of anticancer agents. This review also explores the integration of advanced technologies, such as theranostics and artificial intelligence, to optimize NP design and functionality for personalized medicine. However, challenges remain, including issues related to toxicity, drug resistance, and manufacturing scalability. Addressing these barriers requires interdisciplinary research focused on developing stimuli-responsive NPs, improving biocompatibility, and incorporating multimodal therapeutic platforms. Although substantial progress has been made, this review is limited by the paucity of clinical trials validating NP efficacy and safety in diverse patient populations. Future endeavors should prioritize translational research to bridge the gap between preclinical innovations and clinical applications, ensuring that these transformative technologies benefit a broader spectrum of cancer patients. The review underscores the immense potential of NPs in redefining cancer treatment while advocating for sustained research to address existing limitations and unlock their full therapeutic promise.</p>\",\"PeriodicalId\":10845,\"journal\":{\"name\":\"Current pharmaceutical design\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical design\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113816128368718250320060346\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128368718250320060346","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

癌症继续对全球健康构成重大挑战,需要创新的治疗方法来克服化疗和放疗等传统治疗方法的局限性。纳米颗粒(NPs)由于其独特的物理化学特性,可以实现靶向药物递送,降低全身毒性,提高治疗效果,已成为癌症治疗的有前途的工具。这篇全面的综述深入探讨了基于np的药物递送机制,突出了被动和主动靶向策略。它分类和讨论了不同的NP类型,包括聚合物、脂质和金属纳米颗粒,强调了它们在提高抗癌药物的生物利用度和特异性方面的应用。本文还探讨了先进技术的整合,如治疗学和人工智能,以优化个性化医疗的NP设计和功能。然而,挑战依然存在,包括与毒性、耐药性和制造可扩展性相关的问题。解决这些障碍需要跨学科研究,重点是开发刺激反应性NPs,提高生物相容性,并结合多模式治疗平台。尽管已经取得了实质性进展,但由于缺乏临床试验验证NP在不同患者群体中的有效性和安全性,本综述受到限制。未来的努力应优先考虑转化研究,以弥合临床前创新和临床应用之间的差距,确保这些变革性技术使更广泛的癌症患者受益。该综述强调了NPs在重新定义癌症治疗方面的巨大潜力,同时提倡持续研究,以解决现有的限制并释放其全部治疗前景。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Nanoparticles as Novel Drug Delivery Systems for Cancer Treatment: Current Status and Future Perspectives.

Cancer continues to pose a significant global health challenge, demanding innovative therapeutic approaches to overcome the limitations of conventional treatments like chemotherapy and radiotherapy. Nanoparticles (NPs) have emerged as promising tools for cancer therapy due to their unique physicochemical properties that enable targeted drug delivery, reduced systemic toxicity, and enhanced therapeutic efficacy. This comprehensive review delves into the mechanisms of NP-based drug delivery, highlighting both passive and active targeting strategies. It categorizes and discusses diverse NP types, including polymeric, lipid-based, and metallic nanoparticles, emphasizing their applications in enhancing the bioavailability and specificity of anticancer agents. This review also explores the integration of advanced technologies, such as theranostics and artificial intelligence, to optimize NP design and functionality for personalized medicine. However, challenges remain, including issues related to toxicity, drug resistance, and manufacturing scalability. Addressing these barriers requires interdisciplinary research focused on developing stimuli-responsive NPs, improving biocompatibility, and incorporating multimodal therapeutic platforms. Although substantial progress has been made, this review is limited by the paucity of clinical trials validating NP efficacy and safety in diverse patient populations. Future endeavors should prioritize translational research to bridge the gap between preclinical innovations and clinical applications, ensuring that these transformative technologies benefit a broader spectrum of cancer patients. The review underscores the immense potential of NPs in redefining cancer treatment while advocating for sustained research to address existing limitations and unlock their full therapeutic promise.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信